

## FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2010

### FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2010

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter ended 31.03.2010 (Unaudited)	Quarter ended 31.03.2009 (Unaudited)	Year ended 31.03.2010 (Audited)	Year ended 31.03.2009 (Audited)
1.	a. Net Sales/Income from Operations	32,732	22,160	116,309	91,234
	b. Other Operating Income	880	812	3,555	2,754
2.	Expenditure				
	a. (Increase)/decrease in stock in trade and Work in Progress	(1,718)	367	(3,895)	(2,677)
	b. Consumption of raw materials	16,965	8,792	55,414	39,887
	c. Purchase of traded goods	1,092	1,124	3,217	3,201
	d. Power cost	1,911	1,552	6,725	7,122
	e. Employee cost	2,609	1,954	9,966	8,200
	f. Depreciation and amortisation	2,027	1,925	7,973	7,428
	g. Other expenditure	3,116	3,182	15,670	13,637
	h. Total	<b>26,002</b>	<b>18,896</b>	<b>95,070</b>	<b>76,798</b>
3.	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items (1-2)</b>	<b>7,610</b>	<b>4,076</b>	<b>24,794</b>	<b>17,190</b>
4.	Other Income	567	1,013	3,028	4,724
5.	<b>Profit before Interest &amp; Exceptional Items (3+4)</b>	<b>8,177</b>	<b>5,089</b>	<b>27,822</b>	<b>21,914</b>
6.	Interest	62	90	199	494
7.	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>8,115</b>	<b>4,999</b>	<b>27,623</b>	<b>21,420</b>
8.	Tax Expense, net of reversals	851	(203)	2,787	1,040
9.	<b>Net Profit from Ordinary Activities after Tax but before exceptional items (7-8)</b>	<b>7,264</b>	<b>5,202</b>	<b>24,836</b>	<b>20,380</b>
10.	Exceptional Items (Net of Tax expense) [Refer note 3 below]	-	(2,788)	-	(9,201)
11.	<b>Net Profit from ordinary activities after tax (9+10)</b>	<b>7,264</b>	<b>2,414</b>	<b>24,836</b>	<b>11,179</b>
12.	Paid-up equity share capital (Face value of Rs. 5 each)	10,000	10,000	10,000	10,000
13.	Reserves excluding revaluation reserves			146,534	127,393
14.	a. Earnings per share before Exceptional Items (Face value of Rs. 5 each)				
	Basic	3.72	2.70	12.77	10.56
	Diluted	3.71	2.65	12.57	10.27
	b. Earnings per share after Exceptional Items (Face value of Rs. 5 each)				
	Basic	3.72	1.25	12.77	5.79
	Diluted	3.71	1.24	12.57	5.64
15.	Public Shareholding				
	- Number of Shares	78,165,024	78,165,024	78,165,024	78,165,024
	- Percentage of shareholding	39.08%	39.08%	39.08%	39.08%
16.	Promoter and Promoter Group Shareholding				
	a) Pledged / encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	121,834,976	121,834,976	121,834,976	121,834,976
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	60.92%	60.92%	60.92%	60.92%

### CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND ENDED MARCH 31, 2010

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter ended 31.03.2010 (Unaudited)	Quarter ended 31.03.2009 (Unaudited)	Year ended 31.03.2010 (Audited)	Year ended 31.03.2009 (Audited)
1.	a. Net Sales/Income from Operations	65,684	46,626	236,782	160,867
	b. Other Operating Income	137	1,193	693	1,796
		<b>65,821</b>	<b>47,819</b>	<b>237,475</b>	<b>162,663</b>
2.	Expenditure				
	a. (Increase)/decrease in stock in trade and Work-in-progress	(1,505)	1,338	(3,707)	(5,470)
	b. Consumption of raw materials	38,639	24,882	135,606	87,228
	c. Purchase of traded goods	673	195	1,867	2,086
	d. Power cost	1,948	1,478	6,763	6,933
	e. Employee cost	6,389	5,102	24,498	18,110
	f. Depreciation and amortisation	3,668	3,062	14,014	11,025
	g. Other expenditure	6,501	4,657	24,606	19,645
	h. Total	<b>56,313</b>	<b>40,713</b>	<b>203,647</b>	<b>139,556</b>
3.	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items (1-2)</b>	<b>9,508</b>	<b>7,106</b>	<b>33,828</b>	<b>23,107</b>
4.	Other Income	745	837	3,009	4,659
5.	<b>Profit before Interest &amp; Exceptional Items (3+4)</b>	<b>10,253</b>	<b>7,943</b>	<b>36,837</b>	<b>27,766</b>
6.	Interest	332	613	1,689	1,766
7.	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>9,921</b>	<b>7,330</b>	<b>35,148</b>	<b>26,000</b>
8.	Tax Expense, net of reversals	1,435	(157)	4,867	1,184
9.	<b>Net Profit from Ordinary Activities after Tax but before exceptional items (7-8)</b>	<b>8,486</b>	<b>7,487</b>	<b>30,281</b>	<b>24,816</b>
10.	Exceptional Items (Net of Tax expense) [ Refer note 3 below]	-	(4,143)	-	(14,719)
11.	<b>Net Profit from ordinary activities before minority interest (9+10)</b>	<b>8,486</b>	<b>3,344</b>	<b>30,281</b>	<b>10,097</b>
12.	Add/(Less): Minority interest [ Refer note 4 below]	(424)	(828)	(956)	(713)
13.	Share of Losses in Associate	-	(28)	-	(72)
14.	<b>Net Profit from ordinary activities after tax (11 + 12 + 13)</b>	<b>8,062</b>	<b>2,488</b>	<b>29,325</b>	<b>9,312</b>
15.	Paid-up equity share capital (Face value of Rs. 5 each)	10,000	10,000	10,000	10,000
16.	Reserves excluding revaluation reserves			165,690	140,980
17.	a. Earnings per share before exceptional items (Face value of Rs. 5 each)				
	Basic	4.15	3.44	15.08	12.45
	Diluted	4.08	3.34	14.84	12.12
	b. Earnings per share after exceptional items (Face value of Rs. 5 each)				
	Basic	4.15	1.29	15.08	4.83
	Diluted	4.08	1.25	14.84	4.69
18.	Public Shareholding				
	- Number of Shares	78,165,024	78,165,024	78,165,024	78,165,024
	- Percentage of shareholding	39.08%	39.08%	39.08%	39.08%
19.	Promoter and Promoter Group Shareholding				
	a) Pledged / encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	121,834,976	121,834,976	121,834,976	121,834,976
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	60.92%	60.92%	60.92%	60.92%

### SEGMENT RESULTS OF CONSOLIDATED RESULTS FOR THE QUARTER AND ENDED MARCH 31, 2010

(Rs. in Lakhs)

Particulars	Quarter ended 31.03.2010 (Unaudited)	Quarter ended 31.03.2009 (Unaudited)	Year ended 31.03.2010 (Audited)	Year ended 31.03.2009 (Audited)
Segment revenue				
a. Pharma	58,285	39,988	208,710	138,561
b. Contract Research & Manufacturing Services	8,160	7,134	30,403	23,594
<b>Total</b>	<b>66,445</b>	<b>47,122</b>	<b>239,113</b>	<b>162,155</b>
Less: Inter-segment revenue	761	496	2,331	1,288
Net sales	65,684	46,626	236,782	160,867
Segment results				
Profit before interest, depreciation and tax from each segment				
a. Pharma	15,341	10,127	59,157	40,244
b. Contract Research & Manufacturing Services	2,537	2,483	9,076	6,646
<b>Total</b>	<b>17,878</b>	<b>12,610</b>	<b>68,233</b>	<b>46,890</b>
Less: Interest	332	613	1,689	1,766
Depreciation and amortisation	3,668	3,062	14,014	11,025
Unallocated corporate expenses	4,840	2,623	21,085	13,542
Unallocated corporate income	(882)	(1,018)	(3,702)	(5,443)
<b>Profit before tax and exceptional items</b>	<b>9,920</b>	<b>7,330</b>	<b>35,147</b>	<b>26,000</b>
Capital employed				
a. Pharma	116,726	113,211	116,726	113,211
b. Contract Research	23,373	20,110	23,373	20,110
c. Minority Interest	(3,379)	(2,477)	(3,379)	(2,477)
d. Unallocable	39,065	20,230	39,065	20,230
<b>Total capital employed</b>	<b>175,785</b>	<b>151,074</b>	<b>175,785</b>	<b>151,074</b>

#### Notes:

- The financial results of the Company and the consolidated financial results for the year ended March 31, 2010 have been audited by the statutory auditors of the Company. The results for the quarter have been subjected to limited review by the statutory auditors. The above results have been reviewed by the Audit Committee on April 28, 2010 and approved by the Board of Directors of the Company at their meeting held on April 29, 2010. The Directors have recommended, subject to the approval of the members, dividend of 70% (Rs. 3.50 per share).
- The financial statements for AxiCorp GmbH, Germany ('AxiCorp') a subsidiary company, are drawn upto December 31, 2009 for the purposes of consolidation. Accordingly, the consolidated results of Biocon for the quarter ended March 31, 2010 include the results of AxiCorp for the period from October 01, 2009 to December 31, 2009. The financial statements of other subsidiaries, joint venture company and associate have been drawn up to the same reporting date as that of the Company, i.e. March 31, 2010. In accordance with Accounting Standard 21, adjustments have been made for significant transactions during the period from January 01, 2010 to March 31, 2010.
- Exceptional items:
  - Exceptional items for the quarter and year ended March 31, 2010 is Rs NIL. Exceptional items for the quarter and the year ended March 31, 2009 include mark to market loss in respect of foreign exchange forward contracts including realized gains/losses incurred on termination/cancellation of the said contracts of Rs 2,988 (net of taxes of Rs 265) and Rs 9,401 (net of taxes of Rs 773) in the case of the Company and Rs 4,343 (net of tax of Rs 265) and Rs 14,919 (net of taxes of Rs 773) in respect of the consolidated financial results, respectively.
  - Exceptional items for the year ended March 31, 2009 also include write back of unutilised provision for contingencies of Rs 200 relating to transfer of its enzymes business created in the prior year.

- For the quarter and year ended March 31, 2010, minority interest comprise profits of Rs. 105 (Rs. 200) and Rs. 637 (Rs. 299) attributable to minority shareholders of AxiCorp and Rs. 319 (Rs. 628), Rs. 319 (Rs. 414) attributable to share of losses of the joint venture partner in Biocon Biopharmaceuticals Private Limited.
- During the year ended March 31, 2010, the Company acquired the Active Pharmaceutical Ingredient business of IDL Speciality Chemicals Limited and the same has been appropriately recorded in the books of accounts of the Company.
- During the quarter ended March 31, 2010, the Company has charged off Rs. 738 being the excess consideration over the fair value of the minority interest acquired by a subsidiary of the Company in another subsidiary company.
- On March 31, 2010 the Company entered into an agreement with CIMAB to purchase CIMAB's share of 49% equity shares in BBPL. The sale is yet to be consummated as at March 31, 2010.
- The Company operates in a single business segment of pharmaceuticals.
- In respect of the consolidated financial results, the primary segment reporting has been performed on the basis of business segments. Segments have been identified and reported based on the nature of the products, risks and returns, organizational structure and internal financial reporting systems.
- Total number of shareholder complaints pending at the beginning of the quarter was one. Complaints received during the quarter were 45. All complaints, except one complaint have been resolved as at March 31, 2010.
- The prior period/year figures have been reclassified wherever required to conform to the classification of the current period.

For and on behalf of the Board of Directors

Sd/-  
**Kiran Mazumdar Shaw**  
Chairman & Managing Director

Place: Bangalore

Date: April 29, 2010